The U.S. District Court for the Eastern District of Texas for a third time ruled to set aside certain regulations implementing the No Surprises Act. In this case, the Texas Medical Association, joined by several air ambulance providers and supported by an amicus filed by the AHA, successfully argued that the methodology for how insurers calculate the qualifying payment amount tilts the arbitration process in insurers’ favor. The court specifically disallowed several regulatory provisions related to the QPA calculation, including those that could enable insurers to include in the calculation of QPAs contracted rates for services that providers have not provided, as well as allowing self-insured group health plans to use rates from all plans administered by a third-party administrator in calculating the QPA.  

The federal agencies administering these regulations have not indicated how they will proceed in light of this ruling. Currently, the No Surprises Act arbitration process is on hold as a result of separate litigation challenging other aspects of the No Surprises Act regulations.

Headline
The AHA May 27 filed an amicus brief in the 7th U.S. Circuit Court of Appeals supporting the dismissal of an online tracking lawsuit against a member hospital…
Headline
The departments of Health and Human Services, Labor and the Treasury issued a final rule May 28 intended to improve the functioning of the No Surprises Act…
Headline
The U.S. Court of Appeals for the 5th Circuit April 9 affirmed rulings by a Mississippi district court that rejected requests by Novartis and PhRMA to enjoin…
Headline
The Centers for Medicare & Medicaid Services April 1 released a joint FAQ with the Departments of Labor, the Treasury, and the Office of Personnel…
Headline
The Workgroup for Electronic Data Interchange announced that it is conducting a survey on how health care providers are implementing good faith estimates for…
Headline
The AHA Jan. 26 urged the Health Resources and Services Administration to take immediate action to stop a new Eli Lilly and Company policy from taking effect…